Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23979952 | 0.95 | DDB1 (0.51) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL16221478 | 0.85 | DDB1 (0.46) | CRBNDDB1IKZF3SMN1; SMN2NPC1 | |
| SCHEMBL283716 | 0.84 | CRBN (0.56) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL18900415 | 0.84 | CRBN (0.56) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL24113855 | 0.81 | DDB1 (0.61) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL15943330 | 0.80 | CRBN (0.60) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL19953925 | 0.77 | DDB1 (0.42) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL19954308 | 0.77 | DDB1 (0.42) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL19953926 | 0.77 | DDB1 (0.42) | CRBNDDB1KDM4EMEN1KMT2A | |
| SCHEMBL3649915 | 0.77 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-9834538-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834538-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586929-B2 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129873-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885KDM4E 2974/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885KDM4E 2974/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885KDM4E 2974/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885DDB1 233/4885KDM4E 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.